Latest news
Verrica Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 19:04:20 GMTVerrica: Buy Rating Reiterated on YCANTH Momentum, Pivotal Wart Program Progress, and Strengthened Balance Sheet; $12 Price Target Maintained - TipRanksTipRanks · Fri, 07 Aug 2026 13:41:05 GMTVRCA: Strong YCANTH growth, new credit facility, and advancing pivotal trials drive momentum - TradingViewTradingView · Thu, 06 Aug 2026 22:19:43 GMTVerrica Pharmaceuticals reports Q2 2026 revenue $5.9M, net loss $13.2M; YCANTH demand up - TradingViewTradingView · Thu, 06 Aug 2026 20:37:10 GMTEARNINGS_CALL_TRANSCRIPT_TITLE_FORMATTED - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 20:30:00 GMTVerrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:14:05 GMT